Project Grant R01GM160637
- The National Institute of Biomedical Imaging and Bioengineering, part of the Department of Health and Human Services National Institutes of Health, awarded Massachusetts General Hospital $2,007,744 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop MSEAL, a supramolecular surgical sealant for hemostasis in burn excision surgery. MSEAL is a spray-on, highly adhesive sealant engineered to address...
- The National Heart, Lung, and Blood Institute awarded Worcester Polytechnic Institute $532,935 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the endothelial glycocalyx in sepsis-induced coagulopathy. The research targets sepsis-associated coagulopathy, a condition characterized by uncontrolled thrombosis, large vessel occlusion, and stroke that resists traditional anticoagulation therapies. The project will examine how sepsis...
- The National Institute of General Medical Sciences (part of the National Institutes of Health, Department of Health and Human Services) awarded $393,800 to the Terasaki Institute for Biomedical Innovation on September 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop immunomodulatory nanofibrous modular aerogels for chronic wound healing. The research addresses chronic wounds affecting approximately 6.5 million Americans by combining three engineered...
- This Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,250,000 in funding to Biodevek Inc., a Boston-based small business, to advance the development of a novel hydrogel delivery system for managing gastrointestinal (GI) lesions and bleeding. The project aims to create the first sprayable hemostatic hydrogel solution for endoscopic procedures, with the potential to improve outcomes, reduce...
- The National Institute of General Medical Sciences awarded Brigham and Women's Hospital $445,983 on March 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support cellular therapy research for sepsis and lung injury. The funded work investigates mesenchymal stem/stromal cells and placenta-derived trophoblast stem cells as therapeutic interventions in preclinical models of sepsis and acute lung injury. The laboratory examines mechanisms of biological...
- The National Institute of General Medical Sciences awarded the University of New England $390,500 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to probe cell signaling complexity in wound healing using engineered protein materials. The recipient will investigate how a protein's molecular environment influences its function and how information flows through protein-ligand interactions using engineered proteins and protein-based materials. The work...
- The National Institute of General Medical Sciences awarded $451,000 to The University of Texas MD Anderson Cancer Center on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to dissect the role of extracellular vesicles and matrix in wound healing. The research identifies mechanisms by which fibroblasts respond to tissue injury through extracellular vesicle cargo packaging and extracellular matrix remodeling. The project uses genetically engineered...
- The National Institute of General Medical Sciences awarded The Washington University $200,613 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the role of proton-sensing G protein-coupled receptors in trauma and hemorrhagic shock. The research examines how trauma combined with hemorrhagic shock influences expression and activation of proton-sensing G protein-coupled receptors (GPR4 and GPR68) on cerebral endothelial cells, and whether...
- This $1,017,602 National Science Foundation project grant supports research at North Carolina State University to develop microphysiological models for evaluating the role of age-dependent fibrinogen sialylation in wound healing. The three-year award under the NSF Engineering program (CFDA 47.041) will fund the creation of innovative tissue engineering techniques and microfluidic systems to study interactions between platelets and fibroblasts during wound healing. Researchers aim to better...
- The National Institute of Allergy and Infectious Diseases awarded Beth Israel Deaconess Medical Center, Inc. (doing business as BIDMC) $191,484 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of neutrophil glycosylation in pneumonia susceptibility following traumatic brain injury. The research examines how damage-associated molecular patterns (DAMPs) released after trauma alter innate immune cell function and predispose...
The National Institute of General Medical Sciences awarded Brigham & Womens Hospital Inc. $393,800 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop GLYCOPATCH, a multifunctional trauma adhesive for life-threatening visceral organ injuries. The award supports research into a pectin-based hydrogel sealant designed to stabilize traumatic wounds and deliver site-directed bioactives including procoagulants or antibiotics in resource-limited and point-of-injury environments. The project runs through March 31, 2030, with performance at the recipient's Boston, Massachusetts location. Work encompasses two specific aims: embedding recombinant Factor VIIa, tissue factor, and tranexamic acid into GLYCOPATCH to optimize clot kinetics using rotational thromboelastometry, then testing procoagulant formulations for rapid hemostasis in large-animal hemorrhage models mimicking escalating damage control surgery; and a second aim addressing infection containment through the hydrogel's free volume capacity for antibiotic loading. The project aligns with NIH's priority to develop single-step solutions addressing critical gaps in trauma care.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $393.8k | 7/24/26 |